BioNTech SE (BNTX)
$95.84-1.16%Close
SELLRECOVERY · day 94
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $24.2B
- Beta
- 1.29
- P/E (TTM)
- -12.73
- Short % float
- 0.99%
- Days to cover
- 3.1
- SI change
- +7.5%
- 1W
- -1.84%
- 1M
- -0.92%
- vs SPY 1W
- -2.27%
- vs SPY 1M
- -2.98%
Industry peers
FMP comparable companies · ranked by market cap
- GMABBUYGenmab A/S$22.9BBULLQ 21$37.37+0.81%
- INCYSELLIncyte Corporation$22.6BBEARQ 13$111.36-1.27%
- IBRXBUYImmunityBio, Inc.$10.6BRECOVERYQ 8$10.12-3.71%
- TGTXSELLTG Therapeutics, Inc.$8.5BBEARQ 11$55.27-0.18%
- IOVABUYIovance Biotherapeutics, Inc.$6.5BRECOVERYQ 9$14.56-0.41%
- XNCRSELLXencor, Inc.$1.9BRECOVERYQ 16$25.04+1.66%
- IMCRSELLImmunocore Holdings plc$1.5BBEARQ 2$29.04-1.19%
- IMTXSELLImmatics N.V.$967MCRISISQ 6$7.21-2.96%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on BNTX?
- LOPJLB’s latest quantitative signal on BioNTech SE (BNTX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is BNTX in?
- BioNTech SE (BNTX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does BioNTech SE (BNTX) do?
- BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a fo…